Skip to content
Back
News Coverage

Parker Institute, BMS, and CRI Partner on Immuno-Oncology Research

The Parker Institute for Cancer Immunotherapy, Bristol-Myers Squibb (BMS), and the Cancer Research Institute (CRI) said today they will partner to speed up discovery and development of new immuno-oncology treatments.

The value of the multiyear clinical research collaboration was not disclosed.

BMS becomes the first biopharma to partner with the Parker Institute and CRI. The company said it will solicit clinical research proposals from the Parker Institute and CRI researcher networks, as well as coordinate multisite clinical studies aimed at what the company calls the most difficult questions in cancer research.

Read More

Get Email Updates